Reporting Frequency and Market Monitoring in Reward Crowdfunding Markets

2021 ◽  
Author(s):  
Ties de Kok
Keyword(s):  
Market Monitoring ◽  
Reporting Frequency

Attracting Attention: Cheap Managerial Talk and Costly Market Monitoring

2005 ◽  
Author(s):  
Andres Almazan ◽  
Sanjay Banerji ◽  
Adolfo De Motta
Keyword(s):  
Market Monitoring

The Scaling Property of Randomness: the Impact of Reporting Frequency on the Perceived Performance of Investment Funds

2005 ◽  
Author(s):  
Nigel Finch ◽  
Guy Ford ◽  
Suresh Cuganesan ◽  
Tyrone M. Carlin
Keyword(s):  
Investment Funds ◽  
Perceived Performance ◽  
Scaling Property ◽  
Reporting Frequency ◽  
The Impact

Interim Reporting Frequency and the Mispricing of Accruals

2018 ◽  
Vol 32 (3) ◽  
pp. 29-47
Author(s):  
Shou-Min Tsao ◽  
Hsueh-Tien Lu ◽  
Edmund C. Keung
Keyword(s):  
Financial Reporting ◽  
Stock Prices ◽  
Data Availability ◽  
Financial Reports ◽  
Regulatory Changes ◽  
Sample Composition ◽  
Reporting Frequency ◽  
Over Time ◽  
Jel Classifications ◽  
Accrual Mispricing

SYNOPSIS This study examines the association between mandatory financial reporting frequency and the accrual anomaly. Based on regulatory changes in reporting frequency requirements in Taiwan, we divide our sample period into three reporting regimes: a semiannual reporting regime from 1982 to 1985, a quarterly reporting regime from 1986 to 1987, and a monthly reporting regime (both quarterly financial reports and monthly revenue disclosure) from 1988 to 1993. We find that although both switches (from the semiannual reporting regime to the quarterly reporting regime and from the quarterly reporting regime to the monthly reporting regime) hasten the dissemination of the information contained in annual accruals into stock prices and reduce annual accrual mispricing, the switch to monthly reporting has a lesser effect. Our results are robust to controlling for risk factors, transaction costs, and potential changes in accrual, cash flow persistence, and sample composition over time. These results imply that more frequent reporting is one possible mechanism to reduce accrual mispricing. JEL Classifications: G14; L51; M41; M48. Data Availability: Data are available from sources identified in the paper.

Experts Urge FDA To Use Databases, Post-Market Monitoring To Boost Safety

2007 ◽  
Vol 2 (6) ◽  
pp. 279-280
Author(s):  
Jeffrey L. Fox
Keyword(s):  
Market Monitoring ◽  
Post Market

scholarly journals Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

2019 ◽  
Vol 7 (1) ◽  
pp. e000725 ◽  
Author(s):  
Gian Paolo Fadini ◽  
Mayur Sarangdhar ◽  
Fabrizio De Ponti ◽  
Angelo Avogaro ◽  
Emanuel Raschi
Keyword(s):  
Reporting System ◽  
Immunosuppressive Drugs ◽  
Fournier’S Gangrene ◽  
Rare Occurrence ◽  
Fournier's Gangrene ◽  
Glucose Lowering ◽  
Sodium Glucose Cotransporter ◽  
Definition Of ◽  
Reporting Frequency ◽  
Design And Methods

ObjectiveSodium glucose cotransporter-2 inhibitors (SGLT2i) exert cardiorenal protection in people with diabetes. By inducing glycosuria, SGLT2i predispose to genital infections. In addition, rare occurrence of Fournier’s gangrene (FG) has been reported. We aimed to investigate such association through the U.S. Food and Drug Administration (FDA) adverse event (AE) reporting system (FAERS).Research design and methodsWe mined the FAERS up to 2018q3 (before FDA warning about SGLT2i-associated FG) to retrieve reports including FG as an AE and SGLT2i as suspect or concomitant drugs, and calculated proportional reporting ratios (PRR).ResultsWe retrieved 47 cases of FG and 17 cases of other severe AEs of the genital area associated with SGLT2i. Patients with FG were ~10 years older than those with other severe genital AEs. Overall, 77% occurred in men. Three patients were concomitantly treated with systemic immunosuppressive drugs. Increased reporting frequency emerged for SGLT2i compared with other drugs, with a PRR ranging from 5 to 10. The disproportional reporting of FG with SGLT2i remained robust and consistently significant when restricting to the period when SGLT2i were available, to reports filed for glucose-lowering medications or for drugs with the diabetes indication, and after refining the definition of FG. FG was disproportionally associated with psoriasis and with the combination of immunosuppressants and SGLT2i.ConclusionsAlthough causality cannot be demonstrated, SGLT2i may predispose to FG and other severe genital AEs. Since the use of SGLT2i is expected to increase significantly, clinicians should be aware of these severe, although rare, AEs and their predisposing factors.

Effective market monitoring for surveillance of the Indian electricity market

2009 ◽  
Vol 3 (3) ◽  
pp. 275-292 ◽  
Author(s):  
Prabodh Bajpai ◽  
Sri Niwas Singh
Keyword(s):  
Electricity Market ◽  
Market Monitoring
Sign in / Sign up

Export Citation Format

Share Document